Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
Alnylam Pharmaceuticals·Products & Services·2 segments·Rolls up to Fair Value Measurement Disclosure
Breakdown
| Segment | Q4 '25 | Q1 '26 |
|---|---|---|
| Vutrisiran | $194.15M | $187.94M |
| Zilebesrian | $17.05M | $19.61M |
| Total | — | — |
Segments
VutrisiranView metric
ZilebesrianView metric